{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:33:56Z","timestamp":1791182036867,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.exphem.2010.05.006","type":"journal-article","created":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T06:01:09Z","timestamp":1275026469000},"page":"744-755","source":"Crossref","is-referenced-by-count":43,"title":["In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V"],"prefix":"10.1016","volume":"38","author":[{"given":"Alexandra","family":"B\u00f6hm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Sonneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline V.","family":"Gleixner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Schuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried F.","family":"Pickl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerit-Holger","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Pehamberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Rabitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2010.05.006_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: current concepts in diagnosis and treatment","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2010.05.006_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2010.05.006_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.exphem.2010.05.006_bib4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.006_bib5","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2010.05.006_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2010.05.006_bib7","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2010.05.006_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","article-title":"Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis","volume":"113","author":"Fritsche-Polanz","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2010.05.006_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000048179","article-title":"Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts","volume":"127","author":"Feger","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.exphem.2010.05.006_bib10","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.006_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of \u201cYear 2000 Working Conference on Mastocytosis.\u201d","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.006_bib12","first-page":"291","article-title":"Mastocytosis (mast cell disease)","volume":"Vol. 1","author":"Valent","year":"2001"},{"key":"10.1016\/j.exphem.2010.05.006_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.exphem.2010.05.006_bib14","first-page":"54","article-title":"Mastocytosis (mast cell disease)","volume":"Vol. 2","author":"Horny","year":"2008"},{"key":"10.1016\/j.exphem.2010.05.006_bib15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0145-2126(01)00041-8","article-title":"Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis","volume":"25","author":"Sperr","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.006_bib16","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.006_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.exphem.2010.05.006_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.006_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2010.05.006_bib20","first-page":"399","article-title":"Systemic mastocytosis","volume":"142","author":"Valent","year":"2008","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.exphem.2010.05.006_bib21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2010.05.006_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.006_bib23","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/cncr.22187","article-title":"Novel approaches in the treatment of systemic mastocytosis","volume":"107","author":"Quintas-Cardama","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2010.05.006_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2010.05.006_bib25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0145-2126(02)00073-5","article-title":"Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma","volume":"26","author":"Escribano","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.006_bib26","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.006_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","article-title":"Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.006_bib28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2362.2008.02036.x","article-title":"Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis","volume":"38","author":"Aichberger","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.exphem.2010.05.006_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2010.05.006_bib30","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.006_bib31","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2010.05.006_bib32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.leukres.2008.09.027","article-title":"Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V","volume":"33","author":"Ustun","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.006_bib33","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated forms of c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2010.05.006_bib34","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.006_bib35","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2010.05.006_bib36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.006_bib37","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.4049\/jimmunol.147.12.4224","article-title":"IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells","volume":"147","author":"Sillaber","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2010.05.006_bib38","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.006_bib39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1439-0264.2002.00398.x","article-title":"Morphological and biochemical aspects of apoptosis, oncosis and necrosis","volume":"31","author":"Van Cruchten","year":"2002","journal-title":"Anat Histol Embryol"},{"key":"10.1016\/j.exphem.2010.05.006_bib40","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1084\/jem.20050807","article-title":"Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation","volume":"202","author":"Zappulla","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2010.05.006_bib41","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.iac.2006.05.003","article-title":"KIT mutations in mastocytosis and their potential as therapeutic targets","volume":"26","author":"Gotlib","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.exphem.2010.05.006_bib42","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood.V98.13.3784","article-title":"Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells","volume":"98","author":"Schernthaner","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.006_bib43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.leu.2401649","article-title":"2-Chloro-2'-deoxyadenosine induces apoptosis through the Fas\/Fas ligand pathway in human leukemia cell line MOLT-4","volume":"14","author":"Nomura","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.05.006_bib44","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/15257770600894311","article-title":"Inhibition of the ERK pathway promotes apoptosis induced by 2-chloro-2'-deoxyadenosine in the B-cell leukemia cell line EHEB","volume":"25","author":"Smal","year":"2006","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.exphem.2010.05.006_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000048185","article-title":"Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression","volume":"127","author":"Valent","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.exphem.2010.05.006_bib46","first-page":"S75","article-title":"Adverse and beneficial immunological effects of purine nucleoside analogues","volume":"38","author":"Dighiero","year":"1996","journal-title":"Hematol Cell Ther"},{"key":"10.1016\/j.exphem.2010.05.006_bib47","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1468-3083.2004.00969.x","article-title":"Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia","volume":"18","author":"Rossini","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.exphem.2010.05.006_bib48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2257.2000.00283.x","article-title":"Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell\u00a0leukaemia at a single institution","volume":"22","author":"Grey","year":"2000","journal-title":"Clin Lab Haematol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1000202X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1000202X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T09:34:22Z","timestamp":1685612062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X1000202X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0301472X1000202X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2010.05.006","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}